1. Home
  2. RYTM vs QBTS Comparison

RYTM vs QBTS Comparison

Compare RYTM & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$115.68

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo D-Wave Quantum Inc.

QBTS

D-Wave Quantum Inc.

HOLD

Current Price

$21.24

Market Cap

6.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
QBTS
Founded
2008
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.8B
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
RYTM
QBTS
Price
$115.68
$21.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
15
Target Price
$131.14
$32.53
AVG Volume (30 Days)
682.0K
17.0M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
28.34
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.34
$81.05
Revenue Next Year
$86.06
$93.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$74.50
$12.75
52 Week High
$122.20
$46.75

Technical Indicators

Market Signals
Indicator
RYTM
QBTS
Relative Strength Index (RSI) 61.49 54.04
Support Level $98.59 $16.94
Resistance Level $122.20 $22.10
Average True Range (ATR) 5.42 1.34
MACD 0.83 0.40
Stochastic Oscillator 82.89 84.57

Price Performance

Historical Comparison
RYTM
QBTS

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About QBTS D-Wave Quantum Inc.

D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.

Share on Social Networks: